Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

The Medicines Company

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of The Medicines Company's 2013 cardiovasular sales performance.

The Medicines Company

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

company. The company points out that its European summary of product characteristics (SmPC) lists data from APOLLO on primary and secondary endpoints, including exploratory cardiac endpoints - long term data from it ... Alnylam has three more RNAi

UK trumpets life sciences post-Brexit ‘sector deal’

UK trumpets life sciences post-Brexit ‘sector deal’ Other projects highlighted in the document include a $100m contract from The Medicines Company to test a cholesterol-lowering drug at the University of Oxford’s clinical trials unit, a £40m ... This ecosystem will deliver for everyone,” he added.

The Medicines Company strengthens board of directors

The Medicines Company strengthens board of directors He said: “ I am delighted to be joining The Medicines Company, especially at such an important time. ... Clive Meanwell, chief executive officer and director of The Medicines Company, said: “We are pleased to welcome someone of Paris’s caliber to

AZ gets EU green light for new antibiotic Zavicefta

AZ gets EU green light for new antibiotic Zavicefta The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of serious Gram-negative bacterial infections requiring hospitalization. ... The Medicines Company also has a candidate called RPXZ7009 in phase III trials

Deal Watch May 2016

Deal Watch May 2016 The CRL refers to a manufacturing issue. ZS-9 was acquired when the company purchased ZS Pharma for $2.7bn. ... 911. The Medicines Company/ Chiesi. Product acquisition. Acquisition of cardiovascular assets Cleviprex, Kengreal and rights to Argatroban.

1 2 3 4 5 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics